Clinicopathological factors and tumor microenvironment markers predicting watch-and-wait discontinuation in 82 patients with follicular lymphoma

被引:3
作者
Yuda, Sayako [1 ,2 ]
Miyagi Maeshima, Akiko [1 ]
Taniguchi, Hirokazu [1 ]
Ito, Yuta [2 ]
Hatta, Shunsuke [2 ]
Suzuki, Tomotaka [2 ]
Makita, Shinichi [2 ]
Fukuhara, Suguru [2 ]
Munakata, Wataru [2 ]
Suzuki, Tatsuya [2 ]
Maruyama, Dai [2 ]
Izutsu, Koji [2 ]
机构
[1] Natl Canc Ctr, Dept Pathol, Tokyo, Japan
[2] Natl Canc Ctr, Dept Hematol, Tokyo, Japan
关键词
follicular lymphoma; Ki‐ 67; antigen; tumor microenvironment; watchful waiting; REGULATORY T-CELLS; HIGH NUMBERS; SURVIVAL; RITUXIMAB; OUTCOMES; STAGE; EXPRESSION; PATTERN; MODEL; RISK;
D O I
10.1111/ejh.13637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives In this study, we aimed to determine the clinicopathological factors influencing the treatment-free period in patients with follicular lymphoma (FL) using a watch-and-wait (WW) strategy. Methods We retrospectively assessed histopathological parameters of 82 patients with FL. Results The median time from diagnosis to WW discontinuation was 62 months (range, 3-138), and median follow-up was 86 months (range, 3-183). Intermediate or high-risk Follicular Lymphoma International Prognostic Index score (P = .012), non-duodenal-type (P = .011), higher numbers of interfollicular CD4(+) (P = .038) and intrafollicular FOXP3(+) cells (P = .024) in the tumor microenvironment, and Ki-67 index >= 10% (P = .031) were significant adverse factors for WW discontinuation in univariate analyses. Conclusion Patients with adverse factors for WW discontinuation should be carefully observed during follow-up.
引用
收藏
页码:157 / 165
页数:9
相关论文
共 30 条
  • [1] Rituximab versus a watch-and-wait approach in patients with advanced- stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial
    Ardeshna, Kirit M.
    Qian, Wendi
    Smith, Paul
    Braganca, Nivette
    Lowry, Lisa
    Patrick, Pip
    Warden, June
    Stevens, Lindsey
    Pocock, Christopher F. E.
    Miall, Fiona
    Cunningham, David
    Davies, John
    Jack, Andrew
    Stephens, Richard
    Walewski, Jan
    Ferhanoglu, Burhan
    Bradstock, Ken
    Linch, David C.
    [J]. LANCET ONCOLOGY, 2014, 15 (04) : 424 - 435
  • [2] High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma
    Carreras, Joaquim
    Lopez-Guillermo, Armando
    Fox, Bridget C.
    Colomo, Lluis
    Martinez, Antonio
    Roncador, Giovanna
    Montserrat, Emili
    Campo, Elias
    Banham, Alison H.
    [J]. BLOOD, 2006, 108 (09) : 2957 - 2964
  • [3] High Numbers of Tumor-Infiltrating Programmed Cell Death 1-Positive Regulatory Lymphocytes Are Associated With Improved Overall Survival in Follicular Lymphoma
    Carreras, Joaquim
    Lopez-Guillermo, Armando
    Roncador, Giovanna
    Villamor, Neus
    Colomo, Lluis
    Martinez, Antonio
    Hamoudi, Rifat
    Howat, William J.
    Montserrat, Emili
    Campo, Elias
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) : 1470 - 1476
  • [4] Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
    Dave, SS
    Wright, G
    Tan, B
    Rosenwald, A
    Gascoyne, RD
    Chan, WC
    Fisher, RI
    Braziel, RM
    Rimsza, LM
    Grogan, TM
    Miller, TP
    LeBlanc, M
    Greiner, TC
    Weisenburger, DD
    Lynch, JC
    Vose, J
    Armitage, JO
    Smeland, EB
    Kvaloy, S
    Holte, H
    Delabie, J
    Connors, JM
    Lansdorp, PM
    Ouyang, Q
    Lister, TA
    Davies, AJ
    Norton, AJ
    Muller-Hermelink, HK
    Ott, G
    Campo, E
    Montserrat, E
    Wilson, WH
    Jaffe, ES
    Simon, R
    Yang, LM
    Powell, J
    Zhao, H
    Goldschmidt, N
    Chiorazzi, M
    Staudt, LM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (21) : 2159 - 2169
  • [6] Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Dreyling, M.
    Ghielmini, M.
    Rule, S.
    Salles, G.
    Vitolo, U.
    Ladetto, M.
    [J]. ANNALS OF ONCOLOGY, 2016, 27 : v83 - v90
  • [7] The architectural pattern of FOXP3-positive T cells in follicular lymphoma is an independent predictor of survival and histologic transformation
    Farinha, Pedro
    Al-Tourah, Abdulwahab
    Gill, Karamjit
    Klasa, Richard
    Connors, Joseph M.
    Gascoyne, Randy D.
    [J]. BLOOD, 2010, 115 (02) : 289 - 295
  • [8] Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project
    Federico, Massimo
    Bellei, Monica
    Marcheselli, Luigi
    Luminari, Stefano
    Lopez-Guillermo, Armando
    Vitolo, Umberto
    Pro, Barbara
    Pileri, Stefano
    Pulsoni, Alessandro
    Soubeyran, Pierre
    Cortelazzo, Sergio
    Martinelli, Giovanni
    Martelli, Maurizio
    Rigacci, Luigi
    Arcaini, Luca
    Di Raimondo, Francesco
    Merli, Francesco
    Sabattini, Elena
    McLaughlin, Peter
    Solal-Celigny, Philippe
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) : 4555 - 4562
  • [9] A proportional hazards model for the subdistribution of a competing risk
    Fine, JP
    Gray, RJ
    [J]. JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1999, 94 (446) : 496 - 509
  • [10] Tumour-immune microenvironment in duodenal-type follicular lymphoma
    Inoue, Hiroaki
    Rai, Shinya
    Tanaka, Hirokazu
    Espinoza, J. Luis
    Watatani, Yosaku
    Kumode, Takahiro
    Serizawa, Kentaro
    Nakayama, Shoko
    Taniguchi, Yasuhiro
    Morita, Yasuyoshi
    Tatsumi, Yoichi
    Ashida, Takashi
    Matsumura, Itaru
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (02) : 243 - 252